Padda, Sukhmani K. http://orcid.org/0000-0002-8691-7754
Reckamp, Karen L.
Koczywas, Marianna
Neal, Joel W.
Kawashima, Jun
Kong, Shengchun
Huang, Daniel B.
Kowalski, Mark
Wakelee, Heather A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
https://doi.org/10.1007/s00280-021-04369-0
Funding for this research was provided by:
gilead sciences
Article History
Received: 18 June 2021
Accepted: 16 October 2021
First Online: 13 November 2021
Declarations
:
: Jun Kawashima reports previous employment and stock with Gilead Sciences, Inc. Shengchun Kong reports previous employment and stock with Gilead Sciences, Inc. Mark Kowalski reports previous employment with Gilead Sciences, Inc. Joel W. Neal reports honoraria from CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape CME, Biomedical Learning Institute CME, MLI PeerView CME, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, and MJH Life Sciences CME; he reports consulting fees for AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda Pharmaceuticals, Eli Lilly, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, and Natera; he reports receiving research funding through his institution from Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GlaxoSmithKline, Janssen, and AbbVie; and he receives royalties from Up To Date. Sukhmani K. Padda received research funding through her institution from EpicentRx, Forty Seven Inc., Bayer, and Boehringer Ingelheim; she has participated in advisory boards and received fees from AstraZeneca, AbbVie, Blueprint Medicines, G1 Therapeutics, Janssen Pharmaceuticals, and Pfizer. Karen L. Reckamp reports grant funding through her institution from AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol Meyers Squibb, Calithera, Daiichi Sankyo, Elevation Oncology, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Molecular Partners, Seattle Genetics, Spectrum, Takeda Pharmaceuticals, Xcovery, and Zeno; she reports receiving consulting fees from Calithera, Euclises, Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, EMD Serono, Genentech, Guardant, Janssen, Eli Lilly, Merck KGaA, Precision Health, Seattle Genetics, Takeda Pharmaceuticals, and Tesaro. Heather A. Wakelee reports receiving grant funding through her institution from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/MedImmune, Bristol Myers Squibb, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead Sciences, Inc., Merck, Novartis, Pharmacyclics, Seattle Genetics, Xcovery, Eli Lilly, and Pfizer; she reports honoraria from Novartis and AstraZeneca; she participated in and received advisory board fees from AstraZeneca, Xcovery, Janssen, Daiichi Sankyo, Blueprint, Mirati, Helsinn, and participated in advisory boards for which she did not receive fees from Merck, Takeda Pharmaceuticals, and Genentech/Roche. Marianna Koczywas and Daniel B. Huang have stated that they have no conflict of interest.
: The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved by an institutional review board at each site before enrollment of a patient.
: All patients provided written informed consent.